Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
AT&T Inc. 4.750% PFD SER C Declares $0.2968 Dividend
J&J Releases Encouraging Data on Talvey Combination Therapies
Achieve, INmune, Lenz Gain on Bullish Initiations From Raymond James
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Forecasting The Future: 13 Analyst Projections For AT&T
AT&T Analyst Ratings
Bristol-Myers Squibb Analyst Ratings
Today's Pre-Market Movers and Top Ratings | COST, DG, BMBL, HPQ and More
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
Biggest Stock Movers Friday: BB, BMY, and More
Bristol-Myers Wins FDA Nod for First-of-its-kind Antipsychotic
Fulcrum Therapeutics Swings up 17% on Pfizer Sickle Cell Drug Setback
Looking Into Verizon Communications's Recent Short Interest
Merck, Bristol-Myers Fail to Convince FDA AdCom on Wider Opdivo, Keytruda Use
How Is The Market Feeling About Altria Group?
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths
Florida Braces for Hurricane Helene, Energy Infrastructure in Storm's Path at Risk
SA Chart: Which Sector Will Benefit the Most From Interest Rate Cuts?
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients